Krystal Biotech opened lower at $307.72, compared with its previous close of $308.81. In the last trading session, the stock traded between $304.06 and $309.68. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Krystal Biotech is now worth
$ 619.48
Giving a profit of
$ 519.48 (519.48%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-2.91 (-0.94%)
Day High
$309.68
Day Low
$304.06
Day Open
$307.72
Prev Close
$308.81
Volume
1,07,766
1W Return
-1.56%
1M Return
-7.86%
3M Return
-6.37%
6M Return
-2.23%
1Y Return
50.69%
Market Cap ($ Mn)
9,065
PE Ratio
44.06
PB Ratio
7.66
PEG Ratio
0.71
ROE
19.22%
ROCE
14.99%
EPS (TTM)
$2.13
1 Week
-1.56%
1 Month
-7.86%
3 Months
-6.37%
6 Months
-2.23%
9 Months
12.20%
TD Cowen maintains Buy on Krystal Biotech, lowers price target to $380
TD Cowen maintains a Buy rating on Krystal Biotech. Price target lowered from $403 to $380. Analyst Ritu Baral issued the revised recommendation.
9 days agoHC Wainwright reiterates Buy on Krystal Biotech, holds $361 target
HC Wainwright & Co. reiterated a Buy rating on Krystal Biotech. Analyst Joseph Pantginis maintained a $361 price target. The rating reflects continued confidence in the company's outlook.
28 days agoKrystal Biotech sees 80% lesion regression with KB113 in Gorlin syndrome
KB113 demonstrated over 80% lesion reduction in Gorlin syndrome trial. Abscopal effect observed with 85.1% regression in non-injected lesions. William Blair deems small dataset encouraging for further development. Krystal Biotech shares rose 0.72% to $333.06 following clinical update.
28 days agoKrystal Biotech stock delivers 43.76% annual return over five years
Krystal Biotech delivered an average annual return of 43.76% over the last five years. The stock outperformed the market by 32.48% on an annualized basis. Current market capitalization stands at $10.10 billion with a share price of $345.55. A $100 investment made five years ago would be worth $595.78 today.
2mo agoKrystal Biotech stock delivers 44.08% annualized return over 5 years
Krystal Biotech posted a 44.08% average annual return over the last five years. The stock outperformed the broader market by 32.97% on an annualized basis. Current market capitalization stands at $10.41 billion. A $100 investment from five years ago is now valued at $614.12. Current share price is recorded at $356.19.
2mo agoKrystal Biotech Q2 Results: Net income rises 43% YoY to $54.8 million
Krystal Biotech delivered strong Q2 2026 results with net income rising 43% YoY to $54.8 million, fueled by a 24% increase in VYJUVEK revenue to $119.2 million. Gross margins held at 95% as COGS declined, offsetting higher SG&A from global expansion. The company holds $1.1 billion in cash and expects multiple clinical readouts in 2H 2026, including for KB803, KB407, and KB111.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Krystal Biotech is now worth
$ 619.48
Giving a profit of
$ 519.48 (519.48%)
Note: Past profits do not guarantee future returns.
